Article

Monash University, alongside the University of Missouri and the University of Pennsylvania, has received up to $22.4 million AUD from ARPA-H to advance research in lymphatic pumping. This initiative, part of the GLIDE program, aims to develop oral medicines that restore lymphatic function using allosteric mechanisms.

The five-year project, led by researchers at the Monash Institute of Pharmaceutical Sciences, targets diseases such as lymphedema and rheumatoid arthritis, addressing a significant unmet medical need. The team will design drugs that interact with specific receptor proteins on lymphatic vessels, aiming for safer and more effective treatments.